Our first product was approved and made available to NHS hospitals in May 2019. Our portfolio will increase in 2019 and 2020.
We are proud to have an exceptional partner in Phebra Pty Ltd who have their own modern MHRA and FDA approved manufacturing facility which has ample capacity to supply UK demand. In addition, because of the mutual recognition agreements in place between the regulatory authorities of the UK and Australia supply of finished product into the UK from Australia, is straightforward and fast.
Indicated for the treatment of low-intermediate risk acute promyelocytic leukaemia, this is a novel presentation of arsenic trioxide. The Summary of Product Characteristics can be found at https://www.medicines.org.uk/ emc/product/10278/smpc
Arsenic Trioxide Phebra is a generic product which offers several advantages to the NHS;